Antifibrotic vitamin D analogs

Journal of Clinical Investigation

Volumn 123, Issue 11, 2013, Pages 4570-4573

  Bonventre, Joseph V ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFIBROTIC AGENT; MESSENGER RNA; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA; VITAMIN D; VITAMIN D DERIVATIVE; VITAMIN D RECEPTOR;

ADAPTIVE IMMUNITY; ARTICLE; CANCER SUSCEPTIBILITY; CHRONIC KIDNEY DISEASE; GENE EXPRESSION; HUMAN; KIDNEY FIBROSIS; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 84887440352     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI72748     Document Type: Article

References (19)

1. Eckardt KU, et al. Evolving importance of kidney disease: from subspecialty to global health burden. Lancet. 2013;382(9887):158-169.
2. Kaissling B, Lehir M, Kriz W. Renal epithelial injury and fibrosis. Biochim Biophys Acta. 2013; 1832(7):931-939.
3. Massagué J. TGFβ signalling in context. Nat Rev Mol Cell Biol. 2012;13(10):616-630.
4. Yang L, Besschetnova TY, Brooks CR, Shah JV, Bonventre JV. Epithelial cell cycle arrest in G2/M mediates kidney fibrosis after injury. Nat Med. 2010; 16(5):535-543.
5. Bonventre JV, Yang L. Cellular pathophysiology of ischemic acute kidney injury. J Clin Invest. 2011; 121(11):4210-4221.
6. Akhurst RJ, Hata A. Targeting the TGFβ signalling pathway in disease. Nat Rev Drug Discov. 2012; 11(10):790-811.
7. Carlberg C, Seuter S. A genomic perspective on vitamin D signaling. Anticancer Res. 2009; 29(9):3485-3493.
8. Sutton AL, MacDonald PN. Vitamin D: more than a "bone-a-fide" hormone. Mol Endocrinol. 2003; 17(5):777-791.
9. Bookout AL, Jeong Y, Downes M, Yu RT, Evans RM, Mangelsdorf DJ. Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network. Cell. 2006;126(4):789-799.
10. de Boer IH, Ioannou GN, Kestenbaum B, Brunzell JD, Weiss NS. 25-Hydroxyvitamin D levels and albuminuria in the Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis. 2007;50(1):69-77.
11. de Zeeuw D, et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet. 2010;376(9752):1543-1551.
12. Ito I, et al. A nonclassical vitamin D receptor pathway suppresses renal fibrosis. J Clin Invest. 2013; 123(11):4579-4594.
13. Rochel N, Wurtz JM, Mitschler A, Klaholz B, Moras D. The crystal structure of the nuclear receptor for vitamin D bound to its natural ligand. Mol Cell. 2000;5(1):173-179.
14. Nakano Y, et al. Practical synthesis and evaluation of the biological activities of 1α,25-dihydroxyvitamin D3 antagonists, 1alpha,25- dihydroxyvitamin D3-26,23-lactams. Designed on the basis of the helix 12-folding inhibition hypothesis. J Med Chem. 2006;49(8):2398-2406.
15. Ding N, et al. A vitamin D receptor/SMAD genomic circuit gates hepatic fibrotic response. Cell. 2013;153(3):601-613.
16. 3 under physiological conditions. In: Norman AW, Schaefer K, Grigoleit HG, Herrath DV, eds. Vitamin D: Molecular, Cellular, And Clinical Endocrinology. Berlin, Germany: Walter de Gruyter; 1988:143-144.
17. Li YC. Vitamin D receptor signaling in renal and cardiovascular research. Semin Nephrol. 2013; 33(5):433-447.
18. Pludowski P, et al. Vitamin D effects on musculoskeletal health, immunity, autoimmunity, cardiovascular disease, cancer, fertility, pregnancy, dementia and mortality-a review of recent evidence. Autoimmun Rev. 2013;12(10):976-989.
19. Essien E, Goel N, Melamed ML. Role of vitamin D receptor activation in racial disparities in kidney disease outcomes. Semin Nephrol. 2013; 33(5):416-424.